(Q37137001)

18 August 2017

0 references

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials (English)

1 reference

18 August 2017

0 references

0 references

Christine Rummel-Kluge

series ordinal

2

object named as

Christine Rummel-Kluge

1 reference

18 August 2017

4

John M Kane

1 reference

18 August 2017

1

Christoph U Correll

1 reference

18 August 2017

Caroline Corves

3

1 reference

PMCID

2659301

18 August 2017

Stefan Leucht

series ordinal

5

1 reference

PMCID

2659301

18 August 2017

language of work or name

English

0 references

publication date

15 April 2008

1 reference

18 August 2017

Schizophrenia Bulletin

1 reference

18 August 2017

35

1 reference

18 August 2017

2

1 reference

18 August 2017

443-457

1 reference

Benzodiazepines for schizophrenia

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Antidepressants for the negative symptoms of schizophrenia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Glutamatergic drugs for schizophrenia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

14 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

14 September 2017

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBN018

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Schizophrenia, neuroleptic medication and mortality

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Practice guideline for the treatment of patients with schizophrenia, second edition.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Measuring inconsistency in meta-analyses

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Lithium for schizophrenia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Chlorpromazine equivalent doses for the newer atypical antipsychotics

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Bias in meta-analysis detected by a simple, graphical test

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Meta-analysis in clinical trials

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Clozapine in China: a review and preview of US/PRC collaboration

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Depot Phenothiazine Treatment in Acute Psychosis: A Sequential Comparative Clinical Study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Clinical implications of Brief Psychiatric Rating Scale scores

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

What does the PANSS mean?

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Early Prediction of Antipsychotic Response in Schizophrenia

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Combination antipsychotic therapy in clinical practice.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBN018

The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBN018

Augmentation With a Second Antipsychotic in Patients With Schizophrenia Who Partially Respond to Clozapine

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBN018

Electroconvulsive therapy for schizophrenia.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

Carbamazepine for schizophrenia and schizoaffective psychoses

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2659301

The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia

20 October 2018

1 reference

12 December 2020

Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers

1 reference

12 December 2020

Clozapine in treatment-resistant schizophrenics

1 reference

12 December 2020

Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study

1 reference

12 December 2020

Study of the differential behavioral effects of reserpine, chlorpromazine, and a combination of these drugs in chronic schizophrenic patients

1 reference

12 December 2020

ARE TRANQUILIZER COMBINATIONS MORE EFFECTIVE THAN A SINGLE TRANQUILIZER?

1 reference

12 December 2020

Early prediction of antipsychotic nonresponse among patients with schizophrenia

1 reference

12 December 2020

Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Antipsychotic polypharmacy: evidence based or eminence based?

1 reference

12 December 2020

Long-term combination antipsychotic treatment in VA patients with schizophrenia

1 reference

12 December 2020

Identifiers

DOI

10.1093/SCHBUL/SBN018

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

PMCID

2659301